NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital

20260 citationsJournal Articlegold Open Access

Authors

Nora Berg Bjørnevoll · UiT The Arctic University of Norway

Karl Bjørnar Alstadhaug · Nordland Hospital

Abstract

One in three patients achieved NEDA-3 3 years after starting cladribine, with the best outcomes observed in treatment-naïve patients, while its favorable safety profile and convenient dosing support long-term adherence and disease stability.

Topics & Keywords

Multiple Sclerosis Research Studies Chronic Lymphocytic Leukemia Research Multiple Myeloma Research and Treatments

Publication Details

Published in: Frontiers in Neurology

Volume 16, pp. 1698334-1698334

DOI: 10.3389/fneur.2025.1698334

Field-Weighted Citation Impact: 0.00

Command Palette

NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital

Authors

Abstract

Topics & Keywords

Publication Details